Sparks commentary

Healthcare

Sparks

Evaxion (Nasdaq: EVAX) commences Phase II trial extension
Published by Arron Aatkar, PhD

Evaxion has announced that the first patient has been dosed in its one-year extension of the ongoing Phase II trial, which is assessing EVX-01, its personalised cancer vaccine designed by Evaxion’s AI-Immunology platform, in patients with advanced melanoma. This extension should create a more comprehensive data package for the candidate, providing insights into the durability of immune and clinical responses up to three years. Management noted that the trial remains on track for the two-year data readout in H225.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.